Lance Smith, Author at Clinical Trial Recruitment

BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis

by Lance Smith | Jan 21, 2020 | Study Scavenger Clinical Trial Recruitment Platform

BEIJING, China, and CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for...

Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis

by Lance Smith | Jan 21, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Active U.S. Investigational New Drug (IND) status extends Phase 2b clinical study in moderate to severe Ulcerative Colitis (UC) clinical trial to U.S. patients ABX464 Phase 2b UC trial is already ongoing in 15 European countries and Canada Enrollment of first U.S....

Stealth BioTherapeutics Initiates First-in-Human Study of SBT-272

by Lance Smith | Jan 21, 2020 | Study Scavenger Clinical Trial Recruitment Platform

BOSTON, Jan. 21, 2020 /PRNewswire/ — Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced...

Abivax Receives Clearance from U.S. FDA to Initiate Clinical Trials with ABX464 to treat Moderate to Severe Ulcerative Colitis

by Lance Smith | Jan 20, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Active U.S. Investigational New Drug (IND) status extends Phase 2b clinical study in moderate to severe Ulcerative Colitis (UC) clinical trial to U.S. patients ABX464 Phase 2b UC trial is already ongoing in 15 European countries and Canada Enrollment of first U.S....

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

by Lance Smith | Jan 20, 2020 | Study Scavenger Clinical Trial Recruitment Platform

Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1 Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did...